Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Net Margin (2017 - 2025)

Protagonist Therapeutics' Net Margin history spans 9 years, with the latest figure at 602.82% for Q4 2025.

  • For Q4 2025, Net Margin fell 68261.0% year-over-year to 602.82%; the TTM value through Dec 2025 reached 283.87%, down 34805.0%, while the annual FY2025 figure was 283.87%, 34721.0% down from the prior year.
  • Net Margin for Q4 2025 was 602.82% at Protagonist Therapeutics, up from 834.87% in the prior quarter.
  • Across five years, Net Margin topped out at 1031.57% in Q4 2021 and bottomed at 4768.22% in Q2 2022.
  • The 5-year median for Net Margin is 358.2% (2021), against an average of 563.86%.
  • The largest YoY upside for Net Margin was 4212369bps in 2021 against a maximum downside of -1065402bps in 2021.
  • A 5-year view of Net Margin shows it stood at 1031.57% in 2021, then crashed by -103bps to 30.46% in 2022, then soared by 1069bps to 295.11% in 2023, then plummeted by -73bps to 79.78% in 2024, then tumbled by -856bps to 602.82% in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Net Margin are 602.82% (Q4 2025), 834.87% (Q3 2025), and 627.46% (Q2 2025).